• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Molybdate-free sterilization composition containing peracetic acid. A composition is described which comprises (A) an antimicrobial agent comprising peracetic acid; and (B) a reagent mixture comprising a buffer, an anti-corrosion agent and a chelator. The composition may be characterized by the absence of molybdate. The mentioned composition can be dispersed in water to form a liquid sterilizer. The liquid sterilizer can be used to sterilize items, such as instruments, devices or the like, medical, dental, pharmaceutical, veterinary or mortuary.
    公开号:BR112012022317B1
    申请号:R112012022317-8
    申请日:2011-02-02
    公开日:2021-01-05
    发明作者:Phillip P. Fransciskovich；Donald G. Rosenhamer；Kathleen A. Fix；Dana Hall
    申请人:American Sterilizer Company；
    IPC主号:
    专利说明:

    Technical Field
    [001] This invention relates to a composition suitable for sterilizing articles, such as instruments, devices and the like, medical, dental, pharmaceutical, veterinary or mortuary. Background
    [002] Medical, dental, pharmaceutical, veterinary or mortuary instruments and devices, which are exposed to blood or other body fluids, require sterilization or disinfection between each use. Sterilization or liquid disinfection systems are used to clean and decontaminate instruments and devices that cannot withstand high steam sterilization temperatures.
    [003] US 2009/238719 discloses methods and agents for cleaning and disinfecting fragile medical tools.
    [004] EP 1226835 discloses a method of disinfecting areas from the dispersion of an aqueous solution of peracetic acid.
    [005] US 5624634 discloses a composition for medical disinfection.
    [006] US 6589565 discloses non-corrosive sterilizing compositions.
    [007] US 2007/031464 discloses sterilizing compositions and systems.
    [008] EP 1252819 discloses a composition for disinfecting ophthalmic devices.
    [009] US 2009/061017 discloses low corrosion peroxycarboxylic acid antimicrobial compositions, ready for use.
    [010] US 2009/005590 discloses the production of peracids using an enzyme. summary
    [011] This invention relates to a composition comprising (A) an antimicrobial agent comprising peracetic acid; and (B) a reagent mixture comprising a buffer, an anti-corrosion agent and a chelator; the composition being characterized by the absence of molybdate. This composition can be referred to as a sterilizer or a sterilizing mixture. This composition can be dispersed in water to form a liquid sterilizer, which can be referred to as a liquid sterilizing mixture or a sterilizing medium. When used in a sterilizing process, components (A) and (B) can be supplied separately and dispersed in water, either simultaneously or sequentially, at the time the sterilization process is conducted.
    [012] This invention also relates to a process for sterilizing an article comprising bringing the article into contact with the previous liquid sterilizer. This process can be carried out in a sterilization apparatus, the sterilization apparatus comprising a sterilization chamber and a sterilizer introduction system, the process comprising: placing the article in the sterilization chamber; filling the sterilization chamber with water; the flow of water through the sterilizer introduction system in contact with components (A) and (B) to form a liquid sterilizer; the flow of the liquid sterilizer into the sterilization chamber in contact with the article for an effective period of time to sterilize the article; draining the liquid sterilizer from the sterilization chamber; draining the rinse water in the sterilization chamber in contact with the article and removing the article from the sterilization chamber.
    [013] This invention also relates to a process for sterilizing an article in a sterilization container, the process comprising: placing the article in the sterilization container; filling the sterilization container with water; mixing components (A) and (B) with water to form a liquid sterilizer; maintaining the liquid sterilizer in the sterilization container in contact with the article for an effective period of time to sterilize the article; removing the liquid sterilizer from the sterilization container; rinsing the article in the sterilization container with water and removing the article from the sterilization container. Brief Description of Drawings
    [014] In the accompanying drawings, equal references indicate equal parts and characteristics. - Fig. 1 is a flow chart showing a sterilization process that can be used according to the invention. - Fig. 2 is a flow chart showing a filtration system that can be used as the sterilization process illustrated in Fig. 1. - Fig. 3 is a graph showing the concentration of peracetic acid (PAA) over time to a liquid sterilizer based on the formulations described in the Examples, these formulations referring to the formulation of "Example 1" and the formulation of "Example C-1". - Fig. 4 is a pH graph over time for a liquid sterilizer based on the formulation of Example 1 and the formulation of Example C-1. - Fig. 5 is a graph showing the comparative corrosivity resulting over time for a liquid sterilizer based on the formulation of Example 1 and the formulation of Example C-1. - Fig. 6 is a graph showing the chelating capacity required for a liquid sterilizer based on the formulation of Example 1 and the formulation of Example C-1. - Fig. 7 is a graph showing the time of exposure to a sterilizer required to sterilize an article using a liquid sterilizer based on the formulation of Example 1 (6 minutes) and the formulation of Example C-1 (12 minutes). Detailed Description
    [015] All the ranges and limits of reasons described in the specification and in the claims can be combined. It should be understood that, unless specifically indicated, references to "one", "ones", "ones", "the" and / or "the" may include one or more more than one, and that reference to an item in the singular can also include the item in the plural.
    [016] The word "sterilization" refers to rendering a substance incapable of reproduction, metabolism and / or growth. The word "sterilization" includes microbial deactivation. Although sterilization is often taken to refer to a total absence of living organisms, the word can be used here to refer to a substance free of living organisms to an extent that is agreed to be acceptable. Unless otherwise indicated, the word "sterilization" can be used here to also refer to processes less stringent than sterilization, for example, disinfection, sanitization, decontamination, cleaning and the like. Variations of the word “sterilization”, such as sterilizing, sterilizing, etc., can also be used here to refer to and encompass related variants associated with sterilization processes, as well as processes less stringent than sterilization (for example, disinfectant, disinfect , etc.).
    [017] The composition of the invention can comprise a liquid sterilizer, which can be prepared by dispersing or dissolving the components (A) and (B) in water. Water can be obtained from any source. The water may comprise deionized water, drinking water, processed drinking water or the like.
    [018] Component (A) can comprise peracetic acid and, optionally, one or more additional antimicrobial agents. Component (A) can additionally comprise acetic acid, hydrogen peroxide, sulfuric acid and water.
    [019] Component (B) can comprise a builder formulation, which can be used in combination with component (A), to provide buffering capacity (pH modulation), anti-corrosion properties and chelating capacity (slowing down from water). Component (B) can comprise a buffer, an anti-corrosion agent and a chelator.
    [020] The buffer may comprise an alkali metal phosphate, an alkali metal carbonate or a mixture thereof. The alkali metal can comprise sodium or potassium. The buffer may comprise one or more of monosodium phosphate, disodium phosphate, trisodium phosphate, monopotassium phosphate, dipotassium phosphate, tripotassium phosphate, sodium carbonate or a mixture of two or more of the same. Dipotassium phosphate may be preferred.
    [021] The anticorrosive agent may comprise benzotriazole, a sodium salt of benzotriazole, tolyltriazole, a sodium salt of tolyltriazole or a mixture of two or more thereof. Benzotriazole sodium may be preferred. A commercially preferred sodium benzotriazole, which can be used, is available under the trade name Cobratec 40S, which is believed to be a 40% by weight aqueous solution of sodium benzotriazole.
    [022] The chelator may comprise ethylene-diamino-tetra-acetic acid, hydroxy-ethylidene-diphosphonic acid, a sodium salt of each of these acids, or a mixture of two or more of them. A preferred sodium salt of ethylene-diamino-tetra-acetic acid can be the tetrahydrate, of the tetrasodium salt, of ethylene-diamino-tetra-acetic acid. A commercially available tetrahydrate, of the tetrasodium salt, of ethylene-diamino-tetra-acetic acid, which can be used, is available from Akzo Nobel under the trade name Dissolvine 220-S. Dissolvine 220-S is identified by Akzo Nobel as a chelating agent containing 83-85% by weight of tetrahydrate, tetrasodium salt, ethylene-diamino-tetra-acetic acid.
    [023] Component (B) can comprise: disodium phosphate; benzotriazole sodium and tetrahydrate, tetrasodium salt, ethylene-diamino-tetra-acetic acid.
    [024] The weight ratio of component (A) to component (B) can be at least about 0.1, or in the range of about 0.1 to about 1.3, or about 0.1 to about 1.1, or from about 0.15 to about 0.9, or from about 0.15 to about 0.75, or from about 0.2 to about 0, 7. The weight ratio of component (A) to component (B) can be about 0.45 to about 1.3, or about 0.5 to about 1.3, or about 0 , 6 to about 1.3. The weight ratio of peracetic acid to the buffer can be about 0.1 or higher, or about 0.1 to about 3, or about 0.3 to about 3, or about from 0.35 to about 1.5.
    [025] The concentration of peracetic acid in component (A) can be from about 5% to about 60% by weight, or from about 15% to about 45% by weight, or from about 30% to about 40% by weight, or about 35.5% by weight. The concentration of acetic acid in component (A) can be in the range of about 34% to about 62% by weight, or from about 40% to about 55% by weight. The concentration of hydrogen peroxide in component (A) can be in the range of about 5% to about 60% by weight, or from about 6.5% to about 32% by weight. The concentration of sulfuric acid in component (A) can be in the range of about 0.5% by weight to about 2% by weight, or from about 0.75% to about 1.5% by weight. The water concentration in component (A) can be in the range of about 5% to about 60% by weight, or from about 10% to about 50% by weight. A commercially available peracetic acid solution, which can be used as component (A), is available from FMC Corporation under the trade name Peracetic Acid 35%. This solution is believed to contain 35.5% by weight of peracetic acid, 40% by weight of acetic acid, 6.5% by weight of hydrogen peroxide, 1% of sulfuric acid and 17% of free water.
    [026] Component (B) can comprise from about 35% to about 98% by weight, or from about 45% to about 95% by weight, or from about 55% to about 90% by weight , of the buffer. Component (B) can comprise from about 0.5% to about 35% by weight, or from about 1% to about 25% by weight, or from about 2% to about 14% by weight, of the anticorrosive agent. Component (B) can comprise from about 0.1% to about 70% by weight, or from about 0.3% to about 60% by weight, or from about 0.5% to about 55 % by weight of the chelator.
    [027] The liquid sterilizer prepared from components (A) and (B) can comprise an aqueous solution, in which the concentration of component (A) can be in the range of about 0.5 to about 10 grams per liter , or from about 1.2 to about 3.5 grams per liter; and the concentration of component (B) can be in the range of about 3.6 to about 18 grams per liter, or about 5 to about 15 grams per liter. The liquid sterilizer can have a pH in the range of about 2 to about 11, or about 5.5 to about 7. The liquid sterilizer can be referred to as a low temperature liquid sterilizer. This sterilizer can be used in the sterilization of medical, dental, pharmaceutical, veterinary and mortuary devices, and the like, which cannot be subjected to the high temperatures required for steam sterilization.
    [028] An advantage of the composition of the invention is that it is characterized by the absence of molybdate. Another advantage is that the composition can be characterized by the absence of a nonyl phenol ethoxylate. Another advantage is that the composition can be characterized by the absence of a defoaming agent.
    [029] Although the composition of the invention may be characterized by the absence of one or more of the following materials, it should be understood that this does not exclude the possibility that trace amounts of one or more of these materials may be present in component (B). The term "trace amount" can refer to a concentration of about 0.01% by weight or less, or from about 0.0001 to about 0.1% by weight, based on the weight of component (B) . In one embodiment, component (B) can be limited to three components, namely, a buffer, an anti-corrosion agent and a chelator.
    [030] The liquid sterilizer, prepared from components (A) and (B), can be used in any process for sterilizing articles, including processes for sterilizing articles that cannot withstand the high temperatures required for steam sterilization. Articles, which can be sterilized, may include medical, dental, pharmaceutical, veterinary or mortuary instruments (for example, endoscopes), and the like. These can be made of a material comprising brass, copper, aluminum, stainless steel, carbon steel, plastic, glass, adhesive or a combination of two or more of them. The pH of the liquid sterilizer can be in the range of about 2 to about 11, or about 5.5 to about 7. The temperature of the liquid sterilizer, when used in a sterilization process, can be in the range of about from 20 to about 80 ° C, or from about 40 to about 60 ° C. The exposure time to the liquid sterilizer of the article being sterilized can be in the range of about 0.5 to about 240 minutes, or from about 2 to about 60 minutes.
    [031] The process can be carried out on any suitable sterilization device. An example of such a sterilization apparatus is illustrated in Figs. 1 and 2. Referring to Figs. 1 and 2, sterilization apparatus 10 includes panel 22, which is part of a shelter structure (not shown). Panel 22 includes a recess or cavity 24 sized to receive the articles to be sterilized. A tray or container 26 is provided to receive the items to be sterilized. The container 26 is sized to be received inside the recess or cavity 24.
    [032] A manually operated lid 32 is movable between an open position allowing access to cavity 24, and a closed position (shown in Fig. 1) closing or covering cavity 24. A seal element 34 surrounds cavity 24 and forms a fluid-tight seal, that is, airtight and liquid-tight seal, between lid 32 and panel 22, when lid 32 is in a closed position. A latch (not shown) is provided to close and secure the lid 32 in a closed position during a sterilization cycle. The cavity 24 defines the sterilization chamber 36, when the lid 32 is in the closed position.
    [033] A fluid circulation system 40 allows the liquid sterilizer to flow into the sterilization chamber 36 and the liquid sterilizer to circulate in the sterilization chamber 36. The fluid circulation system 40 includes a water inlet line 42, which is connected to a heated water source (not shown). Filter elements 44 and 46 are positioned on the water inlet line 42, to filter out large contaminants that may be present in the incoming water. Filters 44 and 46 can comprise size exclusion filter elements, used to remove particles that exceed a predetermined size. Filter element 46 can be used to filter out smaller particles than filter element 44. Filter element 44 can be used to filter out particles of about 3 μm (micrometers) or larger, and the filter element filter 46 can be used to filter out particles of about 0.1 μm or larger. Pressure sensors (not shown) can be provided to monitor pressure drops through filter elements 44 and 46. A change in pressure drop across each filter element can be indicative of clogging, rupture or the like.
    [034] A viral reduction device 52, for inactivating organisms within the water source, can be provided at the water inlet line 42. The viral reduction device may comprise an ultraviolet (UV) treatment device, for example , a class A device, as specified in NSF / ANSI Standards 55, or an equivalent thereof. An example of such a device would be an ultraviolet light system having a minimum dosage of 40,000 μW / cm2, which may be available from Wedeco Ideal Horizons in Charlotte, North Carolina. The viral reduction device 52 can be positioned downstream of the filter elements 44 and 46, as shown in Fig. 1. Alternatively, the viral reduction device 52 can be positioned in the water inlet line 42 upstream of the filter elements. 44 and 46.
    [035] The water valve 54 can be used to control the flow of water from the water inlet line 42 to the water feeder line 62. The water feeder line 62 includes the filtration system 100, for filter out microscopic organisms and particles from the incoming water and thereby supply a sterile water supply to the fluid circulation system 40. The water feeder line 62 divides into a first branch feeder line 64 and a second branch feeder line 66. The first branch feeder line 64 is connected to container 26 inside chamber 36. The second branch feeder line 66 is connected to chamber 36. Secondary branch feeder line 68 splits from the first branch feeder line 64 and is connected to the inlet portion of the chemical delivery distribution container 72. Distribution container 72 contains components (A) and (B), which, when combined with water a, form the liquid sterilizer used in sterilization chamber 36. Valve 74 controls flow through the first branch feeder line 64 and through the secondary branch feeder line 68. The chemical distribution vessel 72 is positioned inside the well 76, which is formed within panel 22. Flow restrictors 78, on the second branch feeder line 66 and on the secondary branch feeder line 68, regulate the flow of fluid through these lines.
    [036] The branch return line 82 extends from the chemical distribution vessel 72 and is connected to the system return line 88. Likewise, the branch fluid return lines 84 and 86 extend from the container 26 and chamber 36, respectively, and are connected to system return line 88. System return line 88 connects back to water inlet line 42 and fluid feeder line 62. Pump 92 is positioned on system return line 88 and is used to circulate fluid through fluid circulation system 40. Drain line 94 is connected to system return line 88. Drain valve 96 controls fluid flow to the drain line 94.
    [037] Referring to Fig. 2, the water filtration system 100 is positioned within the fluid feeder line 62 and includes filter elements 114 and 134, shown as part of filter sets 110 and 130, respectively. The first filter set 110 includes housing 112 and filter element 114. The second filter set 130 includes housing 132 and filter element 134. Filter elements 114 and 134 are positioned in series on the feeder line fluid 62. A first section 62a, of the fluid feeder line 62, connects the water inlet line 42 to the inlet side of the first filter assembly 110. A second section 62b, of the fluid feeder line 62, connects to water inlet line 42 to the outlet side of the first filter set 110 to the inlet side of the second filter set 130. A third section 62c of fluid feeder line 62 connects the outlet side of the second filter set 130 to the heater 102.
    [038] The filter elements 114 and 134 can be size exclusion filters that retain bacteria. These can be used to filter mycobacterium particles having particle sizes that are nominally about 0.12 μm or larger. Filter elements 114 and 134 may include a cylindrical support layer (not shown) made of material, such as polypropylene, surrounded by a filter membrane, such as a hydrophilic polyvinylidene difluoride (PVDF) filter membrane or a membrane polyether sulfone (PES) filter. The filter membrane may be in the form of a capillary tube or hollow fiber member (or "fiber"), or in the form of a tubular sheath of a film formed on each of the inner or outer surface of a macroporous tubular support, or a laminate sheet or film, or a laminate film deposited on the porous support. Suitable filter elements can be obtained from PTI Technologies of Oxnard, California.
    [039] The filter element 114 includes an annular outer chamber 116 and an inner annular chamber 118. The outer chamber 116 comprises the pre-filtration side, upstream, of the filter element 114, and the inner chamber 118 represents the side filtered downstream of the filtration element 114. The first section 62a of the fluid feeder line 62 communicates with the outer chamber 116, and the second section 62b of the fluid feeder line 62 communicates with the inner chamber 118. A drain line 122 communicates with outer chamber 116. Valve 124 is positioned on drain line 122 to regulate flow from the first filter assembly 110 to a drain.
    [040] The filter element 134 includes an outer chamber 136 and an inner chamber 138. The outer chamber 136 comprises the pre-filtration side, upstream, of the filter element 134, and the inner chamber 138 represents the filtered side, downstream, of the filter element 134. The second section 62b of the feeder line 62 is communicates with outer chamber 136. The third section 62c of feeder line 62 communicates with inner chamber 138. Drain line 142 communicates with outer chamber 136 of the second filter assembly 130. Valve 144 is positioned on the line drain 142 to regulate flow from the second filter assembly 130 to a drain.
    [041] The first and second filter sets 110 and 130 can be previously sterilized before installation, so that the contents of filter sets 110 and 130 can be free of microbial contaminants. Filter sets 110 and 130 can be sterilized during each subsequent processing step.
    [042] Valves 152 and 154 are positioned on feeder line 62 to allow isolation of the first filter set 110. Valve 152 is positioned within the first section 62a of feeder line 62 on the inlet side of the first filter set 110, and valve 154 is positioned in feeder line section 62b on the outlet side of the first filter set 110. Similarly, valves 162 and 164 are positioned in feeder line 62 to allow isolation of second filter set 130 Valve 162 is positioned in the fluid line section 62b on the inlet side of the second filter set 130, and valve 164 is positioned in the fluid feeder line section 62c on the outlet side of the second filter set 130.
    [043] A filter bypass 172 is connected to fluid supply line 62 on opposite sides of the first and second filter sets 110 and 130. One end of contour line 172 is connected to the supply line fluid 62 between the pump 92 and the location where the water inlet line 42 connects to the fluid supply line 62. A directional check valve 174 is positioned between the water inlet line 42 and the bypass line filter 172 to prevent water entering the filter contour line 172. The other end of the filter contour line 172 is connected to feeder line 62 downstream of filter sets 110 and 130, and heater 102 .
    [044] The 180 filter purge piping system, which includes air inlet line 182 and relief line (vent) 188, can be used to supply pressurized, filtered, clean air to circulation system 40. A control valve 184 is positioned within the air inlet line 182 to regulate the flow of air through it. The air in the air inlet line 182 can be operated at a preset, regulated pressure. Air inlet line 182 may include a pressure regulator (not shown) to maintain a desired air pressure, generally constant, within air inlet line 182. Air inlet line 182 divides into two branch return lines 192 and 194. Relief line 188, with control valve 189, is connected to branch lines 192 and 194. Relief line 188 can be used to allow air to be released from the system of water filtration 100 during a filling cycle.
    [045] The first branch line 192 extends through housing 112 of the first filter set 110 and communicates with the outer chamber 116 of the first filter set 110. The control valve 196, in the first branch line 192, regulates the flow of air through it. The second branch line 194 extends through housing 132 of the second filter assembly 130 and communicates with the outer chamber 136 of the second filter assembly 130. A control valve 198 is positioned within the branch line 194 to regulate the flow through it.
    [046] A first pressure sensor 202 is provided through the first section 62a of the system feed line 62 and branch line 192 to feel the pressure on the upstream side of the filter element 114.
    [047] A second pressure sensor 204 is provided through the second section 62b of the system feed line 62 and branch line 194 to feel the pressure on the upstream side of the filter element 134.
    [048] A first leak port line 212 is connected to the first section 62a of the fluid supply line 62 between water inlet valve 54 and valve 152 on the upstream side of the first filter assembly 110. Valve 214 , inside the leak orifice line 212, regulates the flow through it. A flow restrictor 215 is positioned on the leak orifice line 212 to regulate the flow through it.
    [049] A second leak orifice line 216 is connected to the second section 62b of fluid supply line 62 between valve 154 on the outlet side of the first filter assembly 110 and valve 162 on the inlet side of the second filter assembly 130. The valve 218, inside the orifice 216, regulates the flow through it. A flow restrictor 219 is positioned on the leak orifice line 216 to regulate the flow through it.
    [050] Drain line 232 is connected to section 62b of system feeder line 62, on the downstream side of filter element 114. A valve 234 regulates flow through it. A drain line 236 is connected to section 62c of system feed line 62, on the downstream side of filter element 134. A valve 238 regulates flow through it.
    [051] A system microprocessor (not shown) can be used to control the operation of the circulation system 40 and the valves on it. The operation of the circulation system 40 includes a water filling phase, a chemical generation and sterilization phase, a drainage phase, one or more rinsing stages and a filter verification stage.
    [052] Alternative modalities of the water filtration system 100, which can be used, are described in US patent number 7,569,182 B2, in column 12, line 43, up to column 13, line 46, Figs. 3 and 4, these passages and drawings are hereby incorporated by reference.
    [053] A sterilization process can be conducted using the device 10 as follows. One or more articles to be sterilized (for example, medical, dental, pharmaceutical, veterinary or mortuary instruments or devices) are loaded into container 26, which in turn is placed in chamber 36. The articles can be supported in a tray, or in a basket, or a cartridge, or the like (not shown), inside the container.
    [054] Articles can be sterilized using a liquid sterilizer formed from water and components (A) and (B). The components (A) and (B) are placed in the chemical distribution device 72 and placed in contact with the incoming water, to form the liquid sterilizer. At the beginning of the sterilization process, the drain valve 96, in the circulation system 40, is closed, and the water valve 54, in the inlet line 42, is opened to allow heated water to enter the circulation system 40. A water temperature can be in the range of about 20 to about 80 ° C, or from about 40 to about 60 ° C. The incoming water is filtered using the filter elements 44 and 46, in the water inlet line 42, to remove particles larger than a predetermined size. The water can be treated using a viral reduction device 52, in which ultraviolet (UV) radiation is applied to the water to inactivate organisms in it. The water passes through valve 54 and enters circulation system 40. The incoming water is filtered using filter sets 110 and 130, in the feeder line 62, to fill circulation system 40, the sterilization chamber 36 and the container 26.
    [055] Check valve 174, between water inlet valve 54 and filter contour line 172, causes all incoming water to flow through the first and second filter sets 110 and 130, thereby ensuring the filtration of water draining into the appliance 10.
    [056] The incoming water, which is under pressure from an external source, forces the air into the fluid circulation system 40, the sterilization chamber 36 and the container 26 to an over-flow device ) / air (not shown), which can be positioned at the highest point of the device 10. Air within the system migrates towards the overflow device.
    [057] The presence of water, which seeps through the overflow block, is an indication that the device 10 is filled with water. The system controller then causes the water valve to close, thereby stopping the flow of water to the device 10, that is, to the fluid circulation system 40, the sterilization chamber 36 and the container 26. This completes the water filling phase of the process.
    [058] Once the device 10 is filled with water, the system controller starts the chemical mixing and exposure phase of the process. Pump 92 is energized to circulate water through circulation system 40, sterilization chamber 36 and vessel 26. Valve 24 is opened to start the flow of water through chemical distribution vessel 72. Water and reagents ( that is, the components (A) and (B)) positioned in the chemical distribution vessel 72, combine to form the liquid sterilizer. The liquid sterilizer flows into circulation system 40, in which it is circulated through circulation system 40, sterilization chamber 36 and container 26, through pump 92. A portion of the liquid sterilizer drains into sterilization chamber 36, in around container 26, and a portion of the liquid sterilizer flows to and through container 26 and comes into contact with the articles contained therein.
    [059] As indicated by the arrows in Fig. 2, a portion of the circulating liquid sterilizer flows through the filter contour line 172 and a portion of the liquid sterilizer flows through the supply line 62 and filter sets 110 and 130. A The amount of fluid flowing through the respective portions of the system can be controlled by regulating valve 222. The portion of the liquid sterilizer, which flows through the filter feed line 62 and through the first and second filter sets 110 and 130, must be sufficient to ensure the sterilization of the filter elements 114 and 134 upon exposure to the liquid sterilizer. In this regard, the flow of the liquid sterilizer through filter sets 110 and 130 sterilizes filter elements 114 and 134 and inactivates any microbial contamination that may have entered filter sets 110 and 130 during the water filling phase. During each operation of the apparatus 10, the filter elements 114 and 134 can be exposed to the liquid sterilizer and, as a result, be sterilized by the sterilizer. In addition, the liquid sterilizer, which flows over the entire closed-loop fluid circulation system 40, during a sterilization phase, effectively sterilizes the fluid circulation system 40, and the fluid components and conduits that form the same. In other words, the fluid circulation system 40 is sterilized during each sterilization cycle.
    [060] After a predetermined exposure period, the drainage phase can be started. The length of the exposure period can vary from about 0.5 to about 240 minutes, or from about 2 to about 60 minutes. To start the draining phase, the drain valve 96 is opened and the liquid sterilizer is drained from the circulation system 40, the chamber 36 and the container 26.
    [061] After the liquid sterilizer has been drained from the apparatus 10, one or more rinsing steps are performed to rinse any liquid sterilizer and any residual material from the sterilized articles. In this regard, the inlet valve 54 is opened to introduce fresh water to the apparatus 10, in a manner as previously described as the filling phase. All incoming water passes through the water filtration system 100, in which the water entering the circulation system 40 and the sterilization chamber 36 is sterile. After each rinse filling, the rinse water is drained from the apparatus 10, as previously described. The pump 92 can be activated to circulate the rinse water through the device 10. During each phase of filling, circulation and drainage, the fluid / air overflow make-up set operates to prevent microbial contaminants from entering the internal environment within the system. The sterilized article can then be removed from the sterilization chamber. Examples
    [062] A liquid sterilizer is formed by dissolving the components (A) and (B), identified in the table below under the heading “Example 1”, in processed drinking water. The concentration of component (A) is 5.0 grams per liter (g / L), and the concentration of component (B) is 7.7 g / L. This liquid sterilizer is representative of the invention.
    [063] For comparison purposes, another liquid sterilizer is formed by dissolving components (A) and (B) from the table below under the heading “Example C-1” in drinking water. The concentration of component (A) is 5.0 g / L and the concentration of component (B) is 12.1 g / L. This liquid sterilizer is representative of the prior art.
    [064] Component (A) is the same for both Examples 1 and C-1. Component (B) for each Example is different. Component (B), for Example 1, consists of a relatively simple mixture containing three ingredients, while component (B), for Example C-1, consists of a relatively complex mixture containing twelve ingredients. In addition, the weight ratio of component (A) to component (B) is higher for Example 1 than for Example C-1. Table 1



    [065] There are problems with the prior art, as represented by Example C-1, which are overcome with the composition of the invention, as represented by Example 1. These include: (1) The formulation of Example C-1 contains a molybdate . Molybdates are known to protect white metals from oxidative damage. However, molybdates have been identified as chemical pollutants in many municipal water treatment guidelines, with some municipal governments expressing zero tolerance for their presence in streams. (2) The formulation of Example C-1 is complex in that component (B) contains twelve ingredients. The use of such a complex formulation results in the requirement for correspondingly complex production and combination methods, and provides unfavorable interactions between individual ingredients (for example, pie formation and concretions). The formulation of Example C-1 presents greater difficulties from a quality control perspective than the formulation of Example 1. (3) The formulation of Example C-1 requires greater diligence in tracking the destination and distributing the various ingredients in extractable items from processed articles or devices and in the subsequent wastewater stream. (4) The formulation of Example C-1 is more expensive than the formulation of Example 1. (5) The formulation of Example C-1 hardens earlier than the formulation of Example 1, under normal conditions of storage, transport and use . (6) The formulation of Example C-1 may not be suitable for use in a process employing a “flow-able” filter, where sterilization on both sides of the filter is expected to be a necessary prerequisite for eliminating chemical and process by the US Food and Drug Administration (FDA). The formulation of Example 1 can be used in such a process.
    [066] It was assumed in the prior art that, because of the multiple materials and complex designs used in the construction of modern instruments, devices and the like, doctors, dentists, pharmacists, veterinarians and mortuaries (for example, endoscopes), as well as the pH flow that would be expected under normal conditions of use, and the wide range of water hardness that would occur in places, where these sterilization procedures were likely to be performed, that a liquid sterilizing formulation with multiple components would be necessary. As such, component (B) for the formulation of Example C-1 contains twelve ingredients.
    [067] Although there is no doubt about the safety and efficacy of the formulation of Example C-1, it became necessary to modify this formulation in order to facilitate its use with filters suitable for flow in anticipation of new requirements being issued by the FDA . The problem, therefore, was to provide a replacement formulation in order to comply with anticipated FDA requirements and, at the same time, not to sacrifice safety and effectiveness. This was achieved with the formulation of Example 1. With the formulation of Example 1, it was found that a relatively simple formulation could be used, which achieves equivalent or, sometimes, better performance. This was unexpected.
    [068] Numerous of the ingredients in the formulation of Example C-1 have potentially toxic effects at certain concentration levels and this had to be taken into account when designing the replacement formulation. In developing the formulation of Example 1, concentrations relating to acceptable human contact, device tolerance and environmental limitations had to be considered. The fact that these limitations could change over time also had to be considered. For example, certain municipalities have recently expressed concern about the environmental impact of molybdenum in wastewater. Therefore, it became desirable to remove molybdates from the formulation.
    [069] In testing the effects on effectiveness, as a result of reductions in the amount of molybdenum used in the formulation of Example C-1, it was found that other consequences also prevail. For example, the degradation kinetics of peracetic acid in the absence of molybdenum is significantly altered and the pH resulting from the dilution of use is also affected. It was found that, for the formulation of Example 1: (1) the overall flow in pH over time (kinetics) in the presence of typical amounts of buffer, which would be used, would differ significantly from those in the formulation of Example C- 1; (2) degradation of peracetic acid would be effectively eliminated to a degree beyond what would normally be expected; and (3) the liquid corrosivity would not be adversely affected.
    [070] Unexpectedly, it was found that a substantial number of ingredients in component (B) of the formulation of Example C-1 could be removed in supplying the formulation of Example 1, without any apparent unfavorable consequences with respect to compatibility or power. With the formulation of Example 1, it was initially assumed that in order to continue to use the 12-minute exposure for sterilization runs, which had been successfully validated for the formulation of Example C-1, it would be necessary to expose the article being sterilized at a higher concentration of peracetic acid (PAA) over time. It was conceived that this could result in damage to the article being sterilized as a consequence of excessive exposure to severe sterilization conditions. However, it was found that, with the formulation of Example 1, it was possible to achieve power results equivalent to those achieved with the formulation of Example C-1 with a much shorter exposure (ie, about 6 minutes) and without the expected increase in damage with longer exposure time.
    [071] The formulation of Example 1 can be considered as a simplified, single-use, oxidizing chemical formulation, comprising an active component, that is, component (A), and a constructor component, that is, component (B ). The formulation of Example 1 is at least as safe and effective as a germicide like the formulation of Example C-1, and can be used to sterilize both sides of a flowable filter as required to comply with the FDA.
    [072] The assumption in the prior art had been that a complex formulation, such as that provided by Example C-1, is necessary in order to balance the germicidal efficacy with potential damage to the articles being sterilized. Therefore, for example, it was assumed that a molybdate was needed to protect certain metal components from corrosion caused by peracetic acid. However, the formulation of Example 1 is characterized by the absence of a molybdate and, despite this absence, the corrosion that was anticipated without the molybdate is not observed. This was unexpected.
    [073] An increase in the concentration of peracetic acid (PAA) active in the dilution of use is observed when the formulation of Example 1 is used. This is believed to be attributable to the removal of molybdate from the formulation. The extent of the increase in peracetic acid concentration for the formulation of Example 1, when compared to the formulation of Example C-1, was unexpected. With the formulation of Example C-1, the initial concentration of peracetic acid decreases rapidly over time. On the other hand, with the formulation of Example 1, the initial concentration of peracetic acid decreases much less and reaches an approximately constant value over extended periods. This is shown in Fig. 3. Although this increase in the concentration of active peracetic acid can be advantageous for purposes of bactericidal efficacy, it increases the possibility that too much peracetic acid will cause damage to the articles being sterilized.
    [074] The increase in concentration of peracetic acid, which occurs with the formulation of Example 1, was so significant that it was believed to be necessary to shift the resulting imbalance between efficacy and safety that the removal of molybdate appeared to create. However, instead of reintroducing a molybdate, or other modulating ingredient, the relative proportions of the remaining ingredients have been modified to provide the formulation of Example 1. In addition, when using the formulation of Example 1 to form a liquid sterilizer, the relative amount of peracetic acid used can be correspondingly decreased and / or the exposure time of the article being sterilized, which is in contact with the sterilizer, can be correspondingly decreased. Upon removal of the molybdenum, the resulting pH is only marginally modified and is effectively equivalent to that of the formulation of Example C-1, without significantly changing the kinetics in relation to the increase in peracetic acid concentration. This is shown in Fig. 4. This indicates that the required balance between optimal germicidal reactivity (pH 5-7) and optimal device safety (pH 6-8) can be maintained.
    [075] Corrosion testing indicates that the relative resulting corrosivity of the formulation of Example 1, although somewhat greater than that of the formulation of Example 1, is still at an acceptable level. This is shown in Fig. 5. Therefore, with the formulation of Example 1, it is possible to achieve a significant increase in peracetic acid concentration, while maintaining favorable pH and acceptable levels of corrosivity.
    [076] Although the requirements for the levels of chelation capacity required for the formulation of Example 1 are modified from those required for the formulation of the original Example C-1 (140 ppm and 300 ppm, respectively), the formulation of Example 1 had been adjusted to achieve the desired end point water hardness for this new application. This is shown in Fig. 6.
    [077] Because of the simplicity of the formulation of Example 1, the dissolution of dry ingredients proceeds more quickly than with the formulation of Example C-1. Therefore, for example, in a sterilization using the formulation of Example C-1, an 8 minute heating / mixing phase may be necessary, whereas, with the formulation of Example 1, only 1-3 minutes may be necessary. Also due to its simplicity, the formulation of Example 1 gives rise to a dilution of use that is easier to remove by rinsing at the conclusion of the processing cycle, when compared to the formulation of Example C-1. The formulation of Example C-1 may require 4 rinsing cycles to reduce the amount of extractable waste to safe levels, whereas the formulation of Example 1 can reach similar levels after just 2 or less rinsing cycles. Taken cumulatively, these time reductions can result in an overall sterilization cycle, for the formulation of Example 1, which seals less than half the amount of the cycle length required for the formulation of Example C-1. Therefore, with the formulation of Example 1, it may be possible to achieve a significant time-saving benefit, together with the added benefit of retaining the balance of safety and effectiveness, when compared to the use of the formulation of Example C-1.
    [078] Consequently, and unexpectedly, it may be possible to achieve the same exposure dose (mg / L peracetic acid min-1) as the active ingredient (i.e., peracetic acid) for the formulation of Example 1 in less than half of the time required for the formulation of Example C-1. This relationship is shown in Fig. 7.
    [079] The advantages of using the formulation of Example 1, when compared to the formulation of Example C-1, include: (1) The formulation of Example 1 provides a higher total concentration (mg / ml) of peracetic acid over of the entire cycle, which allows for a shorter overall cycle time, while maintaining the equivalent dose. See Figs. 3 and 7. (2) The formulation of Example 1 is characterized by the absence of a molybdate, which is advantageous from an environmental perspective. In fact, the formulation in Example 1 does not contain any material that is currently (in its proposed concentration) not complying with the environmental watch list. (3) The formulation of Example 1 is simple. It contains only those ingredients considered to be necessary to achieve the desired functions. This leads to a much simpler production and blending program with easier quality control measures, and simpler analysis for all ingredients. (4) The formulation of Example 1 allows for the reduction of required rinsing cycles from four to two or less, thus saving cycle time and utility costs for the customer. More than 11 million cycles per year (which is the anticipated market use for the formulation of Example 1), which translates into savings of approximately 60 million gallons of treated water from the municipality used per year. (5) There is no evidence that any of the ingredients in the formulation of Example 1 interact with each other, in any different way, to support safety and effectiveness. (6) The formulation of Example 1 is a much less complex formulation than the formulation of Example C-1 and therefore much less diligence is required in tracking the destination and distributing its ingredients in the extractable items of sterile articles or in subsequent waste stream. (7) The formulation of Example 1 comprises fewer ingredients, which are easier to supply, and which are manufactured by multiple vendors, and are easier to control with respect to their most common specifications. (8) The formulation of Example 1 employs the use of less expensive ingredients and with fewer total ingredients, which reduces overall material costs. (9) The formulation of Example 1 provides better overall shelf life and stability, with a reduced tendency to form pies or to harden, as often occurs with the formulation of Example C-1. (10) The formulation of Example 1 provides faster and more effective dissolution in water to form a liquid sterilizer. (11) The formulation of Example 1 provides a substantially shorter exposure time (less than or equal to 6 minutes for the formulation of Example 1 versus 12 minutes for the formulation of Example C-1). (12)] Although the invention has been explained in relation to several modalities, it must be understood that modifications of it may become evident to technicians specialized in the subject of the technique, when reading the specification. Therefore, it should be understood that the scope of the invention specified herein is intended to include all modifications that may fall within the scope of the claims. 1/1
    权利要求:
    Claims (4)
    [0001]
    1. Method for sterilizing a medical, dental, pharmaceutical, veterinary or mortuary instrument at a temperature in the range of 20 ° C to 80 ° C using a liquid sterilizer, characterized in that it comprises supplying components (A) and (B) separately and dispersing components (A) and (B) supplied in water at the time the sterilization is to be carried out, in which: component (A) consists essentially of 15% to 45% by weight of peracetic acid; 34% to 62% by weight of acetic acid; 6.5% to 32% by weight of hydrogen peroxide; and 0.5% to 2% by weight of sulfuric acid; component (B) consists essentially of 35% to 98% by weight of a buffer, wherein the buffer is selected from the group consisting of an alkali metal phosphate, an alkali metal carbonate or a mixture thereof; 0.5% to 35% by weight of an anti-corrosion agent; and 0.1% to 60% by weight of a chelator; wherein the weight ratio of component (A) to component (B) is in the range of 0.1 to 1.3; wherein component (B) comprises molybdate, nonylphenol ethoxylate and antifoaming agent, respectively, in trace amounts of 0.01% or less by weight.
    [0002]
    2. Method according to claim 1, characterized in that the concentration of component (A) in the aqueous liquid sterilizer is in the range of 0.5 to 10 g / L, the concentration of component (B) in the aqueous liquid sterilizer is in the range range of 3.6 to 18 g / L and the liquid sterilizer has a pH in the range of 2 to 11, or 5.5 to 7.
    [0003]
    3. Method, according to claim 1 or 2, characterized in that it also comprises putting the medical, dental, pharmaceutical, veterinary or mortuary instrument in contact with the liquid sterilizer.
    [0004]
    4. Method according to any one of the preceding claims, characterized in that the period of exposure of the medical, dental, pharmaceutical, veterinary or mortuary instrument to the liquid sterilizer is in the range of 0.5 to 240 minutes, or 2 to 60 minutes .
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012022317B1|2021-01-05|method for sterilization free of molybdate and containing peracetic acid from a medical, dental, pharmaceutical, veterinary or mortuary instrument
    US5077008A|1991-12-31|Anti-microbial composition
    US6656423B1|2003-12-02|Sterile water generator
    JP5247693B2|2013-07-24|Filter assembly for reprocessing equipment
    ES2775398T3|2020-07-27|Process to decontaminate or sterilize an article with a composition containing peroxide and an antimicrobial agent
    US20170281847A1|2017-10-05|Regenerative peritoneal dialysis system
    EP0357238A2|1990-03-07|Anti-microbial composition
    US5078967A|1992-01-07|Method of cleaning, disinfecting and sterilizing hemodialysis apparatus
    US20090178981A1|2009-07-16|Method and apparatus for treating rinse water in decontamination devices
    CN100368310C|2008-02-13|Sterilizer device for water pipeline
    JP2002301149A|2002-10-15|Disinfectant/detergent composition for artificial dialyzer and method for disinfecting and washing artificial dialyzer
    同族专利:
    公开号 | 公开日
    BR112012022317A2|2015-09-29|
    CN102821603A|2012-12-12|
    CA2792028A1|2011-09-09|
    US20120189495A1|2012-07-26|
    US20170208802A1|2017-07-27|
    EP2542061A2|2013-01-09|
    AU2011221495B2|2014-07-17|
    WO2011109136A3|2011-11-24|
    JP5685271B2|2015-03-18|
    US20120230870A1|2012-09-13|
    CA2792028C|2015-02-24|
    AU2011221495A1|2012-09-27|
    EP2542061B9|2022-02-09|
    WO2011109136A2|2011-09-09|
    JP2013521047A|2013-06-10|
    EP2542061B1|2019-06-12|
    MX2012010048A|2012-12-17|
    ES2743723T3|2020-02-20|
    US20110217204A1|2011-09-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4731222A|1986-02-06|1988-03-15|Innovative Medical Technologies|Automated liquid sterilization system|
    CA1321137C|1988-08-08|1993-08-10|Raymond C. Kralovic|Anti-microbial composition|
    US5132099A|1990-12-27|1992-07-21|Mitsubishi Gas Chemical Company, Inc.|Method for producing hydrogen peroxide|
    GB9122048D0|1991-10-17|1991-11-27|Interox Chemicals Ltd|Compositions and uses thereof|
    BR9712070A|1996-09-18|2002-01-15|Metrex Res Corp|Aqueous anti-corrosive disinfectant and sterilizing composition and processes for forming the same, and for disinfecting a surface|
    US6448062B1|1998-10-30|2002-09-10|Metrex Research Corporation|Simultaneous cleaning and decontaminating compositions and methods|
    US6589565B1|1998-11-23|2003-07-08|Ecolab Inc.|Non-corrosive sterilant composition|
    WO2001028961A2|1999-10-15|2001-04-26|Danisco Cultor America, Inc.|Method for the direct esterification of sorbitol with fatty acids|
    DE19962344A1|1999-12-23|2001-07-12|Henkel Ecolab Gmbh & Co Ohg|Methods and agents for cleaning and disinfecting sensitive medical devices|
    JP2001199811A|2000-01-20|2001-07-24|Mitsubishi Gas Chem Co Inc|Aqueous solution containing peracetic acid|
    US6482358B1|2000-02-07|2002-11-19|Steris Inc.|Three part cup for packaging cleaning and sterilizing agents and sequential cutter|
    FR2820042B1|2001-01-26|2006-12-29|Seppic Sa|METHOD FOR THE DISINFECTION OF PREMISES BY THERMONEBULIZATION OF AQUEOUS SOLUTION OF PERACETIC ACID AND SOLUTION IMPLEMENTED IN THE PROCESS|
    FR2823978B1|2001-04-27|2004-03-05|Bioxal|NOVEL DISINFECTANT COMPOSITION FOR OPHTHALMOLOGICAL DEVICES, ITS USE AND THE DISINFECTION METHOD|
    US7001873B2|2001-10-05|2006-02-21|Steris Inc.|Decontamination of surfaces contaminated with prion-infected material with oxidizing agent-based formulations|
    KR100515928B1|2002-08-28|2005-09-20|이진식|A composition for disinfecting and washing medical instruments comprising a surfactant having alcohol groups at the both terminals and a process for the preparation thereof 1|
    US7229599B2|2003-08-01|2007-06-12|Steris Inc.|Chemical delivery container|
    US7569182B2|2003-08-01|2009-08-04|American Sterilizer Company|Filter assembly for a reprocessor|
    US7135142B2|2003-08-01|2006-11-14|Steris Inc.|Filter assembly for a reprocessor|
    AU2006278364B2|2005-08-05|2012-04-19|Hemostasis, Llc|Antimicrobial composition and system|
    US7964378B2|2005-12-13|2011-06-21|E.I. Du Pont De Nemours And Company|Production of peracids using an enzyme having perhydrolysis activity|
    US7723083B2|2005-12-13|2010-05-25|E.I. Du Pont De Nemours And Company|Production of peracids using an enzyme having perhydrolysis activity|
    CN100358801C|2005-12-29|2008-01-02|云南省化工研究院|Potassium tripolyphosphate preparation method|
    US9271494B2|2007-08-30|2016-03-01|Ecolab USA, Inc.|Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions|
    JP2009155270A|2007-12-27|2009-07-16|Fujifilm Corp|Replenisher for antiseptic solution for medical equipment|
    US8025807B2|2008-01-16|2011-09-27|American Sterilizer Company|Method for treating rinse water in decontamination devices|
    US8809392B2|2008-03-28|2014-08-19|Ecolab Usa Inc.|Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents|
    JP2010095448A|2008-10-14|2010-04-30|Fujifilm Corp|Antiseptic solution for medical equipment and method for sterilizing medical equipment|PT2725930E|2011-06-29|2015-06-11|Gen Electric|Molybdate-free sterilizing and pasteurizing solutions|
    CN103523938B|2012-07-06|2015-11-25|上海蓝宇水处理有限公司|Composite disinfection tablet|
    DE102012109758B3|2012-10-12|2014-03-06|Khs Gmbh|Method for cleaning, disinfecting and / or sterilizing packaging materials and / or components of container treatment plants|
    DE102013109089A1|2013-08-22|2015-02-26|Krones Ag|Apparatus for treating containers in a beverage bottling plant|
    CN103749445A|2013-12-31|2014-04-30|中国船舶重工集团公司第七一八研究所|Compound o-phthalaldehyde disinfection concentrated liquid|
    US11039620B2|2014-02-19|2021-06-22|Corning Incorporated|Antimicrobial glass compositions, glasses and polymeric articles incorporating the same|
    US11039621B2|2014-02-19|2021-06-22|Corning Incorporated|Antimicrobial glass compositions, glasses and polymeric articles incorporating the same|
    US9622483B2|2014-02-19|2017-04-18|Corning Incorporated|Antimicrobial glass compositions, glasses and polymeric articles incorporating the same|
    US10869479B2|2014-04-28|2020-12-22|American Sterilizer Company|Wipe for killing spores|
    US10750749B2|2014-04-28|2020-08-25|American Sterilizer Company|Process and composition for killing spores|
    US10463754B2|2014-04-28|2019-11-05|American Sterilizer Company|Process for decontaminating or sterilizing an article|
    WO2016082897A1|2014-11-28|2016-06-02|Ecolab Inc.|Two components disinfecting composition containing peracetic acid and chelating agent|
    JP6122227B1|2015-05-21|2017-04-26|オリンパス株式会社|Endoscope reprocessor|
    EP3289962B1|2015-06-02|2019-08-14|Olympus Corporation|Endoscope reprocessor|
    US10183087B2|2015-11-10|2019-01-22|American Sterilizer Company|Cleaning and disinfecting composition|
    US10645959B2|2016-09-19|2020-05-12|Red Bull Gmbh|Method and device for treating and monitoring the quality of objects comprising metal materials|
    US20180103637A1|2016-10-18|2018-04-19|American Sterilizer Company|Non-aqueous solvent system for sterilant compositions|
    AT519272A1|2016-10-27|2018-05-15|Red Bull Gmbh|Pasteurization plant and method for operating a pasteurization plant|
    MX2019011406A|2017-03-27|2019-12-16|Regeneron Pharma|Sterilisation method.|
    法律状态:
    2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-06-30| B15K| Others concerning applications: alteration of classification|Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 37/16 , A01N 25/22 , A61L 2/18 , A01P 1/00 Ipc: A61L 2/18 (2006.01), A61L 2/10 (2006.01) |
    2020-06-30| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-10-06| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-01-05| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2011, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    US12/718,078|2010-03-05|
    US12/718,078|US20110217204A1|2010-03-05|2010-03-05|Sterilization composition|
    PCT/US2011/023429|WO2011109136A2|2010-03-05|2011-02-02|Sterilization composition|
    [返回顶部]